SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

INOs FDA approval is prompting traders to speculate that the agency may be more receptive to rare-disease treatments, lifting attention on Capricor ahead of deramiocels FDA decision for Duchenne muscular dystrophy. The community is divided: some see the approval, recent data and launch-related hiring as encouraging signals, while others stress that CAPRs outcome is uncertain given prior FDA concerns and debate over the evidence.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure in a sharp semiconductor selloff as traders question whether heavy AI infrastructure spending will deliver sufficient returns, with weak Intel guidance and Amazons elevated capital spending adding to tech-sector jitters. The community is divided between warnings that AI-related investment and financing risks could prolong the decline and dip buyers pointing to strong demand and oversold conditions.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put Precigens PAPZIMEOS in focus, prompting debate over the threat of new competition. Some traders worry about market share, while others argue Precigens first-mover advantage, commercial launch, and full approval temper the risk compared with Inovios accelerated approval.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report, fueled by demand for Mounjaro and Zepbound and a higher full-year revenue outlook, is driving LLYs rally and analyst upgrades. Bullish traders point to continued obesity-drug growth, while skeptics flag the trimmed profit outlook and high valuation.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline significantly during 2027 has fueled a sharp selloff, raising concerns about pricing and CorMedixs largest revenue driver. Traders disagree over whether DaVitas preliminary outlook signals lasting pressure, pointing to CMSs more reassuring payment estimate and arguing the reaction may be excessive.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration sales from Dupixent, are driving attention. Traders are broadly bullish on the sharp rally and breakout, while some are weighing whether the gains can be sustained.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is drawing attention after a sharp selloff tied to Brazils election results and broader weakness in Brazilian-linked stocks. Traders disagree over whether political and market risks signal further downside or create a buying opportunity, with some pointing to the companys continued growth ahead of earnings.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZenecas stronger-than-expected quarterly results and cost-savings plan to support drug development are driving attention, alongside CEO optimism about its pipeline. Traders are reacting to the sharp rise and move above the 200-day average with broadly bullish commentary.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly results beat estimates, but declining user activity and a forecast for lower fourth-quarter bookings have driven a sharp selloff. Traders are largely bearish over slowing growth and monetization, while some view the drop as an overreaction and a buying opportunity.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook, alongside its positioning as an identity-security layer for AI agents, have fueled a sharp cybersecurity-led rally. Traders are divided over whether demand can justify the valuation, with some taking profits or betting on a pullback after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arteris Q2 2026 Earnings Call Transcript

Arteris (NASDAQ:AIP) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensive financial data andread more...

EverCommerce (EVCM) Surges 19.8%: Is This an Indication of Further Gains?

EverCommerce (EVCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arteris (AIP) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Arteris, Inc. (AIP) Reports Q2 Loss, Tops Revenue Estimates

Arteris (AIP) delivered earnings and revenue surprises of -100.00% and +2.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Spotify (SPOT) Q2 Earnings Miss Estimates

Spotify (SPOT) delivered earnings and revenue surprises of -7.34% and +0.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VERX) Q2 Earnings and Revenues Top Estimates

Vertex (VERX) delivered earnings and revenue surprises of +5.26% and +0.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Arteris, Inc. (AIP) Report Negative Earnings Next Week? What You Should Know

Arteris (AIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphenol (APH) Beats Q2 Earnings and Revenue Estimates

Amphenol (APH) delivered earnings and revenue surprises of +13.45% and +5.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Computer and Technology Stocks Lagging  Cisco Systems (CSCO) This Year?

Here is how Cisco Systems (CSCO) and Arteris, Inc. (AIP) have performed compared to their sector so far this year.

Thursday Sector Laggards: Semiconductors, Electronic Equipment & Products

In trading on Thursday, semiconductors shares were relative laggards, down on the day by about 4.4%. Helping drag down the group were shares of Arteris, off about 15.1% and shares of MaxLinear off about 12.1% on the day.

Also lagging the market Thursday are electronic equipmen...

Arteris, Inc. engages in the provision of interconnect and other intellectual property technology. Its products include Non-Coherent NoC IP, Coherent NoC IP, Last-level Cache Ip, and IP Development Technolgy. The company was founded by Philippe Boucard, Cesar Douady, and Alain Henri Roger Fanet in February 2003 and is headquartered in Campbell, CA.

Arteris Inc

AIP Stock Jumps To Record High – Here’s Why This Analyst Raised Their Price Target By Nearly 120%

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Jefferies raised its price target to $35 from $16 and kept a ‘Hold’ rating, according to The Fly.</li><li>The firm wants a clearer visibility into profitability before recommending the stock.</li><li>Rosenblatt believes the data center deals will help drive Arteris’ royalty revenue much sooner than its automotive business.</li></ul>Shares of Arteris, Inc. (AIP) soared to a record high on Wednesday as upbeat brokerage actions and stronger-than-expected first-quarter results fueled bullish investor sentiment around the company’s growth trajectory.Arteris reported a 39% jump in first-quarter (Q1) revenue to $22.9 million, beating Wall Street’s estimates of roughly $21 million, according to Fiscal.ai data. The company posted a net loss of $1.2 million, or $0.03 per share, compared to consensus estimates of a loss of $0.07 per share.<h2 class="st-heading-2">Jefferies Raises AIP Price Target By Nearly 120%</h2>Following the results, Jefferies raised the price target to $35 from $16 and kept a ‘Hold’ rating, according to The Fly. Analyst Kevin Garrigan said demand tied to AI growth is accelerating, with Arteris seeing stronger royalty trends driven by rising exposure to the data center market.However, the firm wants clearer visibility into profitability before turning more positive on the stock.Arteris expects full year (FY) 2026 revenue between $91 million and $95 million and operating loss between $4.5 million and $8.5 million.<h2 class="st-heading-2">Rosenblatt Bets On AIP’s Data Center Deals</h2>Rosenblatt raised its price target on Arteris to $38 from $20 and kept a ‘Buy’ rating, citing new data center licensing wins. The firm believes the data center deals will help drive Arteris’ royalty revenue much sooner than its automotive business, which is seen as a positive for the company.Arteris’ Q1 was marked by major customer wins, including a leading global hyperscaler expanding its adoption of the company’s technology and a memory supplier accelerating the development of high-bandwidth memory chip solutions.<h2 class="st-heading-2">What Do Retail Traders Think Of AIP?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/AIP">AIP</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes remained ‘high.’One user said Arteris will be part of the backbone of Hyperscaler AI Centers.<stembedurl>https://stocktwits.com/Th3M4skedSt0nker/message/653180592</stembedurl>The stock has seen significant buying interest this year, gaining more than 116%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-qucy-stock-surging-today/cZXLNV8ReKJ">This Nano-Cap Drone Stock Surged 70% And Breached A Key Technical Milestone – What’s Driving Today’s Smashing Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arteris reported a 39% jump in first-quarter revenue, beating Wall Street’s estimates, as brokerages chimed in with bullish commentary around its data center business.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$18.80
Prev Close	$20.59
Open	$19.11
Dividend Yield	0.00%
50-Day Moving Average	$22.05
Beta	2.59
Avg. Volume	713,075.48
PE Ratio	-23.47

52-Week High	$50.26
52-Week Low	$12.06
Market Capitalization	$1.01B
EPS (Annual)	-$0.8216
Price to Book	14.92
Revenue Per Employee	$236,050.17

Feed

News

Sentiment

Earnings

Fundamentals

Info

AIP Fundamentals